ReviewPET clinics2018
PET in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin.
Review in PET clinics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Redefining Soft Tissue Sarcoma Imaging: The Expanding Role of Positron Emission Tomography/Computed Tomography: A Review.World journal of nuclear medicine · 2026Review
- What is the utility of whole-body PET/MRI in the staging of myxoid liposarcoma?Skeletal radiology · 2026Article
- Surgical treatment of a giant cardiac hemangioma in right atrium with pulmonary vein compression.European journal of medical research · 2025Article
- Review
- Paratesticular liposarcomas: A rare but crucial diagnosis. Case series and review of literature.Central European journal of urology · 2025Review
- IgG4-related disease-like lesion arising within a well-differentiated liposarcoma/an atypical lipomatous tumor: two cases report.Frontiers in oncology · 2025Article
- The role of positron emission tomography in the evaluation and management of musculoskeletal lesions-a narrative review.Annals of joint · 2025Review
- Predictive Value of Quantitative Parameters ofDiagnostics (Basel, Switzerland) · 2024Article
- Synovial sarcoma: the misdiagnosed sarcoma.EFORT open reviews · 2024Review
- Lymphadenectomy in the treatment of sarcomas - indications and technique.Oncology reviews · 2024Review
- Diagnostic Superiority of Dual-Time Point [Diagnostics (Basel, Switzerland) · 2023Article
- Article
- Prognostic Value of Pre-Treatment [18F]FDG PET/CT Texture Analysis in Undifferentiated Soft-Tissue Sarcoma.Journal of clinical medicine · 2022Article
- Radiographic findings useful for diagnosis of primary chest wall lymphoma without preceding pleural disease: A case report.Respirology case reports · 2022Article
- Total-Body PET Imaging of Musculoskeletal Disorders.PET clinics · 2021Review
- [Resection of soft tissue tumours : Pitfalls, typical complications and prevention strategies].Der Orthopade · 2020Review
- Isolated Solitary Asymptomatic Skeletal Muscle Relapse of High-Grade Lymphoma Detected on SurveillanceIndian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Soft tissue sarcomas (STSs) account for less than 1% of adult solid tumors and about 7% of pediatric malignancies, causing 2% of cancer-related deaths. With the advent of PET-computed tomography (CT), the value of (18) fluorine-2-fluoro-2-deoxy-d-glucose (FDG) PET imaging to improve the management of STSs has been explored. FDG PET imaging has been found useful in restaging and treatment response assessment. This article reviews current knowledge and application of FDG PET-CT in initial diagnosis, staging, restaging, treatment response monitoring, and prognosis, with a brief overview of the most common histologic subtypes of STS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.